Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ for the Treatment of Mild Alzheimer's

LOS ANGELES, Oct. 24, 2023 (GLOBE NEWSWIRE) -- via IBN -- Longeveron Inc. (NASDAQ:LGVN), a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions, today announces that it has been featured in a broadcast via NetworkNewsAudio ("NNA"), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio news release covers Longeveron's recent announcement of positive top-line results from its Phase 2a trial of its investigational product Lomecel-B™ for the treatment of mild Alzheimer's disease.

To hear the audio production, visit: https://www.nnw.fm/fZD28

To read the original press release, visit: https://nnw.fm/ckhHp

"We believe these results provide important validation of both the safety and therapeutic potential of Lomecel-B™ in the treatment of Alzheimer's disease and provide a robust foundation for additional clinical trials in this and other indications," Wa'el Hashad, CEO of Longeveron, stated in the news release. "We look forward to announcing additional biomarker data from this trial, anticipated to be later this month, which may further characterize the clinical effects of Lomecel-B™ in this study population. With our Phase 2 ELPIS II trial in HLHS moving toward anticipated completion in 2024, and our Phase 2 program in Aging-related Frailty progressing in Japan as well, we look forward to meaningful milestones in the near term and to fully realizing the therapeutic potential of Lomecel-B™."

As explained in the original announcement, the primary endpoint of safety for the trial was met based on statistical and medical assessment. There was one Serious Adverse Event (SAE) reported on each Lomecel-B™ treatment group and none on placebo. Each SAE was reviewed and assessed by the Data and Safety Monitoring Board (DSMB) with no safety issues raised. The study safety data were consistent with an established safety profile with no incidence of hypersensitivity, no cases of Alzheimer Related Imagine Abnormalities (ARIA), no clinically asymptomatic microhemorrhages as revealed by Magnetic Resonance Imaging (MRI), and no notable changes in laboratory evaluations and electrocardiogram (EKG).

"These study results with Lomecel-B™ are encouraging," Dr. Jeffrey Cummings, MD, Vice Chair of Research, UNLV Department of Brain Health, added. "The study met its primary safety endpoint and is supported by lack of deterioration in cognitive or atrophy signals. ...

Full story available on Benzinga.com


Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.


Disclaimer Press Release Banner
Related Press Releases
Happy Chinese New Year Tour Helped Ringing in the Lunar New Year with Seven Events in the United States to Showcase Chinese Craftsmanship and Art Forms

Happy Chinese New Year Tour Helped Ringing in the Lunar New...

Faceswap AI Online Tool: Anakin AI Unleash the Digital Creativity for Everyone

Faceswap AI Online Tool: Anakin AI Unleash the Digital Creat...

VPTrade.com Expands Reach: Innovative Trading Platform Now in Latin America and Asia

VPTrade.com Expands Reach: Innovative Trading Platform Now i...

Lana Evanova's Impressionistic Acrylic Paintings Enchant the Art Community at Arte Fiera 2024

Lana Evanova's Impressionistic Acrylic Paintings Enchant the...

ToyHub247.com: A New Destination for Online Toy Shopping

ToyHub247.com: A New Destination for Online Toy Shopping

SASSA Status Check launched an updated tool for grant beneficiaries

SASSA Status Check launched an updated tool for grant benefi...

Embark on a New Era of Travel and Web3-Related Ecosystem with XINTEL – The Gateway to Unprecedented SocialFi

Embark on a New Era of Travel and Web3-Related Ecosystem wit...

Real Street Capital Announces Regulation A+ Offering to Raise $25 Million for REAL STREET BUILD-TO-RENT FUND I, LLC.

Real Street Capital Announces Regulation A+ Offering to Rais...

Announcing the Launch of Kosa Salon SF’s New Website: A New Luxury Hair Salon in San Francisco

Announcing the Launch of Kosa Salon SF’s New Website: A New...